These specific coactivators are associated with poor clinical outcomes and were correlated with high ERβ expression in high-grade breast tumor subtypes, suggesting that they may mediate ERβ proliferation in breast cancer cells [58]. The gene discussed is ESR2; the disease is breast carcinoma.